Bioshares Research on AVR, page-3

Excerpt:

”This is an opportunity for Admedus, either directly with its own TAVR device, or through the outlicensing of ADAPT to market leaders such as Edwards Life Sciences and Medtronic, which markets the Evolut PRO. For example, younger, low risk patients could be implanted with a device that could be functional for l5 years, well in excess of the five years time point when current valves begin to fail.

Anteris Technologies' heart valve products have the potential to deliver functional su- periority to rival products in terms of both durability, tensile strength and mechanical performance, with ADAPT tissue having passed 400,000 cycles of stress testing, equiva- lent to 10 years of human use.“